Since TNBC patients account for about 20% of breast cancer patients, investigators are also studying other important protein biomarkers that have shown promise as targets for breast cancer such as folate receptor (FOLR) or programmed death-ligand 1 (PD-L1)81,82. This evidence concerns the gene FOLR1 and breast carcinoma.